Targeting the fibroblast growth factor receptors for the treatment of cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 748-761

  Lemieux, Steven ^a   Hadden, M Kyle ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antibodies; ATP Binding Site; Cancer; Fibroblast Growth Factor Receptor; Indolinone; Pyrido 2,3 d pyrimidine; Small Molecules; Tyrosine Kinase Inhibitor

Indexed keywords

1 TERT BUTYL 3 [6 (3, 5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO) PYRIDO [2, 3 D] PYRIMIDIN 7 YL] UREA; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 1A6; 2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL] PROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AL 3810; ARQ 068; ARQ 069; ARQ 523; AZD 4547; BRIVANIB; BRIVANIB ALANINATE; CEDIRANIB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EXEL 3261; EXEL 6484; FIBROBLAST GROWTH FACTOR RECEPTOR; FP 1039; GP 369; IMC A1; IMIDAZOPYRIDINE DERIVATIVE; LENVATINIB; LY 2874455; NF 449; NINTEDANIB; NP 603; NVP BGJ 398; ORANTINIB; PD 161570; PD 166866; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PRO 001; PROTEIN KINASE INHIBITOR; R3MAB; SEMAXANIB; SU 4984; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; AUTOPHOSPHORYLATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; DRUG DOSE ESCALATION; ENDOMETRIUM CANCER; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84880173318     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990080     Document Type: Review

References (106)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-225.
2. Takeuchi, K.; Ito, F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull., 2011, 34(12), 1774-1780.
3. Shawver, L.K.; Lipson, K.E.; Fong, T.A.; McMahon, G.; Plowman, G.D.; Strawn, L.M. Receptor tyrosine kinases as targets for the inhibition of angiogenesis. Drug Discov. Today, 1997, 2(2), 50-63.
4. Takahashi, S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol. Pharm. Bull., 2011, 34(12), 1785-1788.
5. Bhargava, P.; Robinson, M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr. Oncol. Rep., 2011, 13(2), 103-111.
6. Raica, M.; Cimpean, A.M. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals, 2010, 3(3), 572-599.
7. Dai, Y. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin. Ther. Pat., 2010, 20(7), 885-897.
8. Bianco, R.; Gelardi, T.; Damiano, V.; Ciardiello, F.; Tortora, G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell. Biol., 2007, 39(7-8), 1416-1431.
9. Chinnaiyan, P.; Harari, P.M. Clinical advancement of EGFR inhibitors in cancer therapy. Methods Mol. Biol., 2006, 327, 189-202.
10. Furdui, C.M.; Lew, E.D.; Schlessinger, J.; Anderson, K.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell, 2006, 21(5), 711-717.
11. Lew, E.D.; Furdui, C.M.; Anderson, K.S.; Schlessinger, J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signaling, 2009, 2, ra6.
12. Mohammadi, M.; Dikic, I.; Sorokin, A.; Burgess, W.H.; Jaye, M.; Schlessinger, J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell Biol., 1996, 16(3), 977-989.
13. Haugsten, E.M.; Wiedlocha, A.; Olsnes, S.; Wesche, J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res., 2010, 8(11), 1439-1452.
14. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P.T.; Roydasgupta, R.; Kuo, W.L.; Lapuk, A.; Neve, R.M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B.M.; Esserman, L.; Albertson, D.G.; Waldman, F.M.; Gray, J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell, 2006, 10(6), 529-541.
15. Kwabi-Addo, B.; Ozen, M.; Ittmann, M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer, 2004, 11(4), 709-724.
16. Chang, H.; Stewart, A.K.; Qi, X.Y.; Li, Z.H.; Yi, Q.L.; Trudel, S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood, 2005, 106(1), 353-355.
17. Patnaik, M.M.; Tefferi, A. Molecular diagnosis of myeloproliferative neoplasms. Expert Rev. Mol. Diagnosis, 2009, 9(5), 481-492.
18. Dellacono, F.R.; Spiro, J.; Eisma, R.; Kreutzer, D. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am. J. Surg., 1997, 174(5), 540-544.
19. Abella, J.V.; Park, M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am. J. Physiol. Endocrinol. Metab., 2009, 296(5), E973-984.
20. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer, 2010, 10(2), 116-129.
21. Katoh, M. Cancer genomics and genetics of FGFR2. Int. J. Oncol., 2008, 33, 233-237.
22. Beenken, A.; Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Disc., 2009, 8, 235-253.
23. Lin, B.C.; Desnoyers, L.R. FGF19 and cancer. Adv. Exp. Med. Biol., 2012, 728, 183-194.
24. Ahmad, I.; Iwata, T.; Lenug, H.Y. Mechanisms of FGFR-mediated carcinogenesis. Biochim. Biophys. Acta., 2012, 1823(4), 850-860.
25. Wesche, J.; Haglund, K.; Haugsten, E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J., 2011, 437(2), 199-213.
26. Connolly, C.J.C.; Hamby, J.M.; Schroeder, M.C.; Barvian, M.; Lu, G.H.; Panek, R.L.; Amar, A.; Shen, C.; Kraker, A.J.; Fry, D.W.; Klohs, W.D.; Doherty, A.M. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 1997, 7(18), 2415-2420.
27. Panek, R.L.; Lu, G.H.; Dahring, T.K.; Batley, B.L.; Connolly, C.; Hamby, J.M.; Brown, K.J. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther., 1998, 286(1), 569-577.
28. Blankley, C.J.; Boschelli, D.H.; Doherty, A.M.; Hamby, J.M.; Klutchko, S.; Panek, R.L. Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. U. S Patent 5,620,981, 1997.
29. Hamby, J.M.; Connolly, C.J.; Schroeder, M.C.; Winters, R.T.; Showalter, H.D.; Panek, R.L.; Major, T.C.; Olsewski, B.; Ryan, M.J.; Dahring, T.; Lu, G.H.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A.J.; Slintak, V.; Nelson, J.M.; Fry, D.W.; Bradford, L.; Hallak, H.; Doherty, A.M. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem., 1997, 40(15), 2296-2303.
30. Ishibe, T.; Nakayama, T.; Okamoto, T.; Aoyama, T.; Nishijo, K.; Shibata, K.R.; Shima, Y.; Nagayama, S.; Katagiri, T.; Nakamura, Y.; Nakamura, T.; Toguchida, J. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin. Cancer Res., 2005, 11(7), 2702-2712.
31. Batley, B.L.; Doherty, A.M.; Hamby, J.M.; Lu, G.H.; Keller, P.; Dahring, T.K.; Hwang, O.; Crickard, K.; Panek, R.L. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci., 1998, 62(2), 143-150.
32. Mohammadi, M.; Froum, S.; Hamby, J.M.; Schroeder, M.C.; Panek, R.L.; Lu, G.H.; Eliseenkova, A.V.; Green, D.; Schlessinger, J.; Hubbard, S.R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J., 1998, 17(20), 5896-5904.
33. Byron, S.A.; Gartside, M.G.; Wellens, C.L.; Mallon, M.A.; Keenan, J.B.; Powell, M.A.; Goodfellow, P.J.; Pollock, P.M. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res., 2008, 68(17), 6902-6907.
34. Pardo, O.E., Latigo, J.; Jeffery, R.E.; Nye, E.; Poulsom, R.; Spencer-Dene, B.; Lemoine, N.R.; Stamp, G.W.; Aboagye, E.O.; Seckl, M.J. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res., 2009, 69(22), 8645-8651.
35. Trudel, S.; Ely, S.; Farooqi, Y.; Affer, M.; Robbiani, D.F.; Chesi, M.; Bergsagel, P.L. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood, 2004, 103(9), 3521-3528.
36. Miyake, M.; Ishii, M.; Koyama, N.; Kawashima, K.; Kodama, T.; Anai, S.; Fujimoto, K.; Hirao, Y.; Sugano, K. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3) inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J. Pharmacol. Exp. Ther., 2010, 332(3), 795-802.
37. de Brito, L.R.; Batey, M.A.; Zhao, Y.; Squires, M.S.; Maitland, H.; Leung, H.Y.; Hall, A.G.; Jackson, G.; Newell, D.R.; Irving, J.A. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk. Res., 2011, 35(9), 1233-1240.
38. Lee, S.H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S.L.; Gelb, A.B.; Heise, C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res., 2005, 11(10), 3633-3641.
39. Ezzat, S.; Huang, P.; Dackiw, A.; Asa, S.L. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin. Cancer Res., 2005, 11(3), 1336-1341.
40. Thompson, A.M.; Connolly, C.J.; Hamby, J.M.; Boushelle, S.; Hartl, B.G.; Amar, A.M.; Kraker, A.J.; Driscoll, D.L.; Steinkampf, R.W.; Patmore, S.J.; Vincent, P.W.; Roberts, B.J.; Elliott, W.L.; Klohs, W.; Leopold, W.R.; Showalter, H.D.; Denny, W.A. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase. J. Med. Chem., 2000, 43(22), 4200-4211.
41. Thompson, A.M.; Delaney, A.M.; Hamby, J.M.; Schroeder, M.C.; Spoon, T.A.; Crean, S.M.; Showalter, H.D.; Denny, W.A. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J. Med. Chem., 2005, 48(14), 4628-4653.
42. Zhou, W.; Hur, W.; McDermott, U.; Dutt, A.; Xian, W.; Ficarro, S.B.; Zhang, J.; Sharma, S.V.; Brugge, J.; Meyerson, M.; Settleman, J.; Gray, N.S. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol., 2010, 17(3), 285-295.
43. Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M.R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem., 2011, 54(20), 7066-7083.
44. The description of a new phase 1 clinical trial to determine the maximum tolerated dose and safety of NVP-BGJ398 in patients with advanced solid malignancies. http://www.clinicaltrials.gov/ ct2/show/NCT01004224?term=bgj398&rank=1
45. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B.K.; Hubbard, S.R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 1997, 276(5314), 955-960.
46. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem., 1998, 41(14), 2588-2603.
47. Lamont, F.R.; Tomlinson, D.C.; Cooper, P.A.; Shnyder, S.D.; Chester, J.D.; Knowles, M.A. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer, 2011, 104(1), 75-82.
48. Paterson, J.L.; Li, Z.; Wen, X.Y.; Masih-Khan, E.; Chang, H.; Pollett, J.B.; Trudel, S.; Stewart A.K. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol., 2004, 124(5), 595-603.
49. Udayakumar, T.S.; Bair, E.L.; Nagle, R.B.; Bowden, G.T. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression. Mol. Carcinogen., 2003, 38(2), 70-77.
50. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L.K.; McMahon, G.; Tang, C. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem., 1999, 42(25), 5120-5130.
51. Sun, L.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGFR2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J. Med. Chem., 2000, 43(14), 2655-2663.
52. Laird, A.D.; Vajkoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; Fong, T.A.; Strawn, L.M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K.P.; McMahon, G.; Cherrington, J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 2000, 60(15), 4152-4160.
53. Hilberg, F.; Roth, G.J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W.J. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res., 2008, 68(12), 4774-4782.
54. Roth, G.J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem., 2009, 52(14), 4466-4480.
55. Antoniu, S.A.; Kolb, M.R. Intedanib, a triple kinase inhibitor of VEGFR, FGFR, and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs, 2010, 13(5), 332-345.
56. Kammasud, N.; Boonyarat, C.; Tsunoda, S.; Sakurai, H.; Saiki, I.; Grierson, D.S.; Vajragupta, O. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2007, 17(17), 4812-4818.
57. Lin, N.; Chen, S.; Pan, W.; Xu, L.; Hu, K.; Xu, R. NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am. J. Physiol. Cell Physiol., 2011, 301(2), C469-477.
58. Huang, W.S.; Metcalf, C.A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R.M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N.I.; Mohemmad, Q.K.; luliucci, J.; Rivera, N.M.; Dalgarno, D.C.; Sawyer, T.K.; Clackson, T.; Shakespeare, W.C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCRABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53(12), 4701-4719.
59. Gozgit, J.M.; Wong, M.J.; Moran, L.; Wardwell, S.; Mohemmad, Q.K.; Narasimhan, N.I.; Shakespeare, W.C.; Wang, F.; Clackson, T.; Rivera, V.M. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther., 2012, 11(3), 690-699.
60. rd, Tyner, J.W.; Loriaux, M.M.; Corbin, A.S.; Wardwell, S.; Ning, Y.; Keats, J.A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T.K.; Dalgarno, T.C.; Deininger, M.W.; Druker, B.J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.
61. O'Hare, T.; Deininger, M.W.; Eide, C.A.; Clackson, T.; Druker, B.J. Targeting the BCR-ABL signaling pathway in therapyresistant philadelphia chromosome-positive leukemia. Clin. Cancer Res., 2011, 17(2), 212-221.
62. Bhide, R.S.; Cai, Z.W.; Zhang, Y.Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L.J.; Borzilleri, R.M.; Zheng, X.; Wu, L.I.; Barrish, J.C.; Kim, S.H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R. Sr.; Kukral, D.; Hunt, J.T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-ol (BMS540215) an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem., 2006, 49(7), 2143-2146.
63. Cai, Z.W.; Zhang, Y.; Borzilleri, R.M.; Qian, L.; Barbosa, S.; Wei, D.; Zheng, X.; Wu, L.; Fan, J.; Shi, Z.; Wautlet, B.S.; Mortillo, S.; Jeyaseelan, R. Sr.; Kukral, D.W.; Kamath, A.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Barrish, J.C.; Robl, J.A.; Hunt, J.T.; Lombardo, L.J.; Fargnoli, J.; Bhide, R.S. Discovery of brivanib alaninate (S)-(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem., 2008, 51(6), 1976-1980.
64. Bhide, R.S.; Lombardo, L.J.; Hunt, J.T.; Cai, Z.W.; Barrish, J.C.; Galbraith, S.; Jeyaseelan, R. Sr.; Mortillo, S.; Wautlet, B.S.; Krishnan, B.; Kukral, D.; Malone, H.; Lewin, A.C.; Henley, B.J.; Fargnoli, J. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther., 2010, 9(2), 369-378.
65. A press release detailing the brivanib phase II trial results. http://www.natap.org/2012/newsUpdates/010412_01.htm
66. Zhao, G.; Li, W.; Chen, D. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad-spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Res., 2011, 10(11), 2200-2210.
67. Chen, D.; Li, H.-Y.; Zhao, G. Vinyl indazolyl compounds. WO Patent 2010129509 A1, 2010.
68. The description of a new phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and efficacy of LY2874455 in patients with advanced and/or metastatic cancer. http://www.clinicaltrials.gov/ct2/show/NCT01212107?term= ly2874455&rank=1
69. Renhowe, P.A.; Pecchi, S.; Shafer, C.M.; Machajewski, T.D.; Jazan, E.M.; Taylor, C.; Antonios-McCrea, W.; McBride, C.M.; Frazier, K.; Wiesmann, M.; Lapointe, G.R.; Feucht, P.H.; Warne, R.L.; Heise, C.C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J.M.; Wernette-Hammond, M.E.; Harris, A.L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors. J. Med. Chem., 2009, 52(2), 278-292.
70. Lee, S.H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S.L.; Gelb, A.B.; Heise, C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res., 2005, 11(10), 3633-3641.
71. Trudel, S.; Li, Z.H.; Wei, E.; Wiesmann, M.; Chang, H.; Chen, C.; Reece, D.; Heise, C.; Stewart, A.K. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 2005, 105(7), 2941-2948.
72. The description of a phase 1 clinical trial to analyze the bioequivalence of dovitinib capsules and tablets in patients with advanced solid tumors. http: www.clinicaltrials.gov/ct2/show/ NCT01421004?term=tki258&phase=0&rank=7
73. The description of a phase 2 clinical trial to evaluate the safety and efficacy of TKI258 in various forms of endometrial cancer. http://www.clinicaltrials.gov/ct2/show/NCT01379534?term=tki258 &phase=1&rank=1
74. The description of a phase 3 clinical trial to evaluate the safety and efficacy of Dovitinib compared to Sorafenib in patients with metastatic renal cell carcinoma. http://www.clinicaltrials.gov/ct2/ show/NCT01223027?term=tki258&phase=2&rank=1
75. Squires, M.; Ward, G.; Saxty, G.; Berdini, V.; Cleasby, A.; King, P.; Angibaud, P.; Perera, T.; Fazal, L.; Ross, D.; Jones, C.G.; Madin, A.; Benning, R.K.; Vickerstaffe, E.; O'Brien, A.; Frederickson, M.; Reader, M.; Hamlett, C.; Batey, M.A.; Rich, S.; Carr, M.; Miller, D.; Feltell, R.; Thiru, A.; Bethell, S.; Devine, L.A.; Graham, B.L.; Pike, A.; Cosme, J.; Lewis, E.J.; Freyne, E.; Lyons, J.; Irving, J.; Murray, C.; Newell, D.R.; Thompson, N.T. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol. Cancer Ther., 2011, 10(9), 1542-1552.
76. ndAACR Annual Meeting, Orlando, Florida, 2011.
77. Braun, K.; Rettinger, J.; Ganso, M.; Kassack, M.; Hildebrandt, C.; Ullmann, H.; Nickel, P.; Schmalzing, G.; Lambrecht, G. NF449: A subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2001, 364(3), 285-290.
78. Krejci, P.; Murakami, S.; Prochazkova, J.; Trantirek, L.; Chlebova, K.; Ouyang, Z.; Aklian, A.; Smutny, J.; Bryja, V.; Kozubik, A.; Wilcox, W.R. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J. Biol. Chem., 2010, 285(27), 20644-20653.
79. Wedge, S.R.; Kendrew, J.; Hennequin, L.F.; Valentine, P.J.; Barry, S.T.; Brave, S.R.; Smith, N.R.; James, N.H.; Dukes, M.; Curwen, J.O.; Chester, R.; Jackson, J.A.; Boffey, S.J.; Kilburn, L. L; Barnett, S.; Richmond, G.H.; Wadsworth, P.F.; Walker, M.; Bigley, A.L.; Taylor, S.T.; Cooper, L.; Beck, S.; Jürgensmeier, J.M.; Ogilvie, D.J. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res., 2005, 65(10), 4389-4400.
80. Takeda, M.; Arao, T.; Yokote, H.; Komatsu, T.; Yanagihara, K.; Sasaki, H.; Yamada, Y.; Tamura, T.; Fukuoka, K.; Kimura, H.; Saijo, N.; Nishio, K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res., 2007, 13(10), 3051-3057.
81. The description of a phase 3 clinical trial to evaluate the efficacy of cediranib and lomustine in patients with recurrent glioblastoma. http://www.clinicaltrials.gov/ct2/show/NCT00777153?term=azd21 71&phase=2&rank=2
82. Foote, K.M.; Theoclitou, M.; Thomas, A.P.; Buttar, D. Acylaminopyrazoles as FGFR inhibitors. WO Patent 2008075068, 2008.
83. Gavine, P.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M.J.; Brooks, A.N.; Klinowska, T. AZD4547: An orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res., 2012, 72(8), 2045-2056.
84. The description of a phase 1 clinical trial to evaluate the safety of AZD4547 in Japanese patients who have advanced solid malignancies. http://www.clinicaltrials.gov/ct2/show/NCT01213160?term=azd45 47&rank=4
85. The description of a phase 2 clinical trial to evaluate the safety and efficacy of AZD4547 monotherapy compared to paclitaxel in patients with advanced gastric adenocarcinoma. http://www. clinicaltrials.gov/ct2/show/NCT01457846?term=azd4547&rank=2
86. Funahashi, Y.; Tsuruoka, A.; Matsukura, M.; Haneda, T.; Fukuda, Y.; Kamata, J.; Takahashi, K.; Matsushima, T.; Miyazaki, K.; Nomoto, K.; Watanabe, T.; Obaishi, H.; Yamaguchi, A.; Suzuki, S.; Nakamura, K.; Mimura, F.; Yamamoto, Y.; Matsui, J. Nitrogencontaining aromatic derivatives. US Patent No. 7,612,092 B2, 2009.
87. Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer, 2008, 122(3), 664-671.
88. The description of a phase 3 clinical trial to evaluate the efficacy of E7080 in patients with 131I-refractory differentiated thyroid cancer. http://www.clinicaltrials.gov/ct2/show/NCT01321554?term= e7080&phase=2&rank=1
89. Zhou, Y.; Chen, Y.; Tong, L.; Xie, H.; Wen, W.; Zhang, J.; Xi, Y.; Shen, Y.; Geng, M.; Wang, Y.; Jiang, H.; Luo, C.; Lin, L.; Ding, J. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti angiogenic and antitumor activity via targeting VEGFR, FGFR, and PDGFR. J. Cell. Mol. Med., 2012, In Press.
90. Bello, E.; Colella, G.; Scarlato, V.; Oliva, P.; Berndt, A.; Valbusa, G.; Serra, S.C.; D'Incalci, M.; Cavalletti, E.; Giavazzi, R.; Damia, G.; Camboni, G. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res., 2011, 71(4), 1396-1405.
91. The description of a phase 1 clinical trial to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of E-3810/AL3810 in patients with advanced solid tumors. http://www.clinicaltrials.gov/ct2/show/ NCT01283945?term=e-3810&rank=3
92. ndEORTC-NCIAACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, 2010.
93. Ravindranathan, K.P.; Mandiyan, V.; Ekkati, A.R.; Bae, J.H.; Schlessinger, J.; Jorgensen, W.L. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J. Med. Chem., 2010, 53(4), 1662-1672.
94. Eathiraj, S.; Palma, R.; Hirschi, M.; Volckova, E.; Nakuci, E.; Castro, J.; Chen, C.-R.; Chan, T.C.K.; France, D.S.; Ashwell, M.A. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases. J. Biol. Chem., 2011, 286(23), 20677-20687.
95. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 2010, 10(5), 317-327.
96. Sun, H.D.; Malabunga, M.; Tonra, J.R.; DiRenzo, R.; Carrick, F.E.; Zheng, H.; Berthoud, H.-R.; McGuinness, O.P.; Shen, J.; Bohlen, P.; Leibel, R.L.; Kussie, P. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab., 2007, 292(3), E964-E976.
97. Sun, H.; Shen, J.; Tonra, J.R. Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof. WO Patent 2005037235, 2005.
98. Rauchenberger, R.; Borges, E.; Thomassen-Wolf, E.; Rom, E.; Adar, R.; Yaniv, Y.; Malka, M.; Chumakov, I.; Kotzer, S.; Resnitzky, D.; Knappik, A.; Reiffert, S.; Prassler, J.; Jury, K.; Waldherr, D.; Bauer, S.; Kretzschmar, T.; Yayon, A.; Rothe C. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J. Biol. Chem., 2003, 278(40), 38194-38205.
99. Keats, J.J.; Reiman, T.; Maxwell, C.A.; Taylor, B.J.; Larratt, L.M.; Mant, M.J.; Belch, A.R.; Pilarski, L.M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 2003, 101(4), 1520-1529.
100. Qing, J.; Du, X.; Chen, Y.; Chan, P.; Li, H.; Wu, P.; Marsters, S.; Stawicki, S.; Tien, J.; Totpal, K.; Ross, S.; Stinson, S.; Dornan, D.; French, D.; Wang, Q.-R.; Stephan, J.-P.; Wu, Y.; Wiesmann, C.; Ashkenazi, A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest., 2009, 119(5), 1216-1229.
101. Desnoyers, L.R.; Pai, R.; Ferrando, R.E.; Hotzel, K.; Le, T.; Ross, J.; Carano, R.; D'Souza, A.; Qing, J.; Mohtashemi, I.; Ashkenazi, A.; French, D.M. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene, 2008, 27(1), 85-97.
102. Bai, A.; Meetze, K.; Vo, N.Y.; Kollipara, S.; Mazsa, E.K.; Winston, W.M.; Weiler, S.; Poling, L.L.; Chen, T.; Ismail, N.S.; Jiang, J.; Lerner, L.; Gyuris, J.; Weng, Z. GP369, an FGFR2-IIIbspecific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res., 2010, 70(19), 7630-7639.
103. Bosch, E.; Hollenbaugh, D.; Lee, E.; Qin, M.; Sadra, S. Compositions and methods of treating disease with FGFR fusion proteins. US Patent 7,678,890 B2, 2010.
104. Zhang, H.; Masuoka, L.; Baker, K.; Sadra, A.; Bosch, E.; Brennan, T.; Doberstein, S.; Goodworth, G.; Hestir, K.; Hollenbaugh, D.; Long, L.; Qin, M.; Williams, L.T.; FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. AACR-NCI-EORTC Int. Conf. on Molecular Targets and Cancer Therapeutics, San Francisco, 2007.
105. stAACR Annual Meeting, Washington DC, 2010.
106. Tolcher, A.; Papadopoulos, K.; Patniak, A.; Heath, E.; Prokop, T.; Thayer, S.; Zanghi, J.; Keer, H.N.; LoRusso, P. Preliminary results of a dose escalation study of the fibroblast growth factor (FGF) "trap" FP-1039 (FGFR1:Fc) in patients with advanced malignancies. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, 2010.